Mindpeak vs Visiopharm (2026)
Both sell biomarker scoring AI marked for diagnostic use in Europe and research use only in the United States, differing in hosting and partners. Mindpeak lists 11 CE-IVD products for breast HER2, ER, PR and Ki-67 and lung PD-L1, reported IVDR certification in September 2026, and hosts its service itself or distributes through PathAI's AISight. Visiopharm's APPs cover breast biomarkers and metastasis detection, lung PD-L1 and prostate cancer under IVDR certification, are validated to Agilent assays and sold with Agilent, and run on the web, on premises or hybrid.
- You already run PathAI's AISight, which distributes Mindpeak's algorithms.
- You want the vendor to host the service.
- Multiplex immunofluorescence quantification matters to your research.
- You want on premises or hybrid deployment.
- Your laboratory runs Agilent assays and the Omnis platform.
- You want trial evidence from routine use: UMC Utrecht's CONFIDENT-B trial tested the metastasis APP in diagnosis.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Mindpeak and Visiopharm are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Mindpeak | Visiopharm |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2018 | 2001 |
| Headquarters | Hamburg, Germany | Hoersholm, Denmark |
| Website | mindpeak.ai | visiopharm.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Hamburg based computational pathology company, with a US entity in Cambridge, Massachusetts, focused on biomarker quantification from H&E, immunohistochemistry and multiplex immunofluorescence images. It lists 11 CE-IVD products, covering breast HER2, ER, PR and Ki-67 and lung PD-L1, reported IVDR certification in September 2026, and states that its other products are research use only; it has no FDA clearance.
Source: AI Health Index, September 2026
Danish pathology image analysis company whose diagnostic products are packaged as APPs, deep learning algorithms for specific tasks: HER2, Ki67, ER and PR scoring and metastasis detection in breast cancer, PD-L1 in non-small cell lung cancer, and prostate cancer. The CE-IVD APPs are certified under the EU IVDR for diagnostic use in the EU and UK and are not sold for diagnosis in the United States, where research APPs are offered; the company describes the PD-L1 APP as its ninth IVDR certification.
Source: AI Health Index, September 2026
Questions buyers ask
How do Mindpeak and Visiopharm work with the EHR?
For Mindpeak, the algorithm reaches the pathologist through someone else's product.
With Visiopharm, the integrations page names Sectra IDS7 and Proscia Concentriq AP, describes analysis triggered automatically from laboratory information system metadata, and states that the Sectra integration uses Sectra standards with no custom changes, shows overlays and results in the Sectra primary viewer, and can upload on-slide controls for internal quality testing. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Mindpeak and Visiopharm?
In Mindpeak's case, a study by Abele and colleagues assessed the Breast Ki-67 and ER/PR products for quantifying Ki-67, ER, and PR, finding reliability across a wide range of image variance and pathologist confirmation, and concluding the tools can improve interobserver agreement in real world clinical settings.
For Visiopharm, the company links the paper and reports the same site's positive business case. For the PD-L1 APP it describes a study across three European sites against a multi reader reference, and metastasis detection verification on breast and colorectal data from three sites. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Mindpeak and Visiopharm leave to the clinician?
Mindpeak ships both region of interest products, where the pathologist selects the area analyzed, and whole slide analysis.
In Visiopharm's case, the APPs run fully automated with no manual interaction up to the point of pathologist review, and the company describes the output as objective decision support delivered for review rather than a diagnosis. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Mindpeak's general terms grant it a perpetual, sublicensable right to use analyzed images, including to retrain its AI. Neither is FDA cleared. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.